Poner atención a la diversidad de voces es fundamental a medida que continuamos con nuestra meta de escuchar, aprender y actuar contra el racismo y la discriminación.
Site Search
The Cystic Fibrosis Foundation has awarded up to $5.6 million to Microbion Corporation to develop a novel, inhaled antibiotic to treat drug-resistant bacterial infections in people with cystic fibrosis.
Thirty-three new projects are being funded as part of the Foundation's $100 million Infection Research Initiative.
The U.S. Food and Drug Administration has approved the use of ivacaftor (Kalydeco®) for children as young as 6 months.
The Cystic Fibrosis Foundation has awarded up to $7 million to Enterprise Therapeutics to develop a compound that targets a non-CFTR chloride channel in lung cells. If successful, the drug could help mucus become more hydrated and easier to clear from the lungs of all people with CF, regardless of their CFTR mutations.
The Cystic Fibrosis Foundation announced today that it has licensed a compound to the biopharmaceutical company AbbVie to develop into a potential CFTR modulator treatment.
The Foundation, in collaboration with external community advisors, finalizes recommendations in area of Community to help foster more inclusion and improve the experiences of Black people living with and impacted by cystic fibrosis.
At a meeting hosted by the Cystic Fibrosis Foundation, private insurers, state Medicaid officials, care center providers, health experts and people with CF and their families came together to discuss innovative ways to continue improving high quality CF care on February 4.